JCR: Journal of Clinical Rheumatology最新文献

{"title":"Impact of Methotrexate Discontinuation on the Immunogenicity of COVID-19 Vaccines in Patients With Rheumatoid Arthritis.","authors":"Carolina A Isnardi, Margarita Landi, Leonel Cruces, Pablo Maid, Claudia Calle Montoro, María A Alfaro, Brian M Roldán, Andrea B Gómez Vara, Pamela Giorgis, Roberto A Ezquer, María G Crespo Rocha, Camila R Reyes Gómez, María Á Correa, Osvaldo L Cerda, Marcos G Rosemffet, Virginia Carrizo Abarza, Santiago Catalan Pellet, Miguel Perandones, Cecilia Reimundes, Yesica Longueira, Gabriela Turk, María F Quiroga, Natalia Laufer, María C de la Vega, Gustavo Citera, Guillermo J Pons-Estel, Emilce E Schneeberger","doi":"10.1097/RHU.0000000000002166","DOIUrl":"10.1097/RHU.0000000000002166","url":null,"abstract":"","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":"e189-e191"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142620699","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lower Back Pain in Granulomatosis With Polyangiitis: Iliopsoas Muscle Abscess Due to Nontuberculous Mycobacteria.","authors":"Hirotaka Yamamoto, Yoshinori Taniguchi","doi":"10.1097/RHU.0000000000002150","DOIUrl":"10.1097/RHU.0000000000002150","url":null,"abstract":"","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":"e187"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142465902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Remote Behaviorally Designed Intervention to Promote Physical Activity in Patients With Knee Osteoarthritis: Results of a Pilot Randomized Clinical Trial.","authors":"Rachel L Gillcrist, Caleigh R Doherty, Marianna Olave, Juliana Bonilla, Bryant R England, Katherine Wysham, Mercedes Quinones, Carla R Scanzello, Alexis Ogdie, Daniel K White, Tuhina Neogi, Joshua F Baker","doi":"10.1097/RHU.0000000000002148","DOIUrl":"10.1097/RHU.0000000000002148","url":null,"abstract":"<p><strong>Objective: </strong>We evaluated a behaviorally designed intervention utilizing gamification and social support to improve physical activity and reduce symptoms in patients with osteoarthritis of the knee (KOA).</p><p><strong>Methods: </strong>Veterans with KOA, aged 40-80 years, were enrolled in this randomized controlled trial. Participants received a Fitbit and completed a 2- to 4-week baseline period. A Web-based platform administered biweekly surveys after randomization and tracked physical activity. Participants selected a daily step goal that was 33%, 40%, or 50% above their baseline. The intervention arm received game playing aspects and a social support partner to advance weekly step performance while the control arm only received weekly updates. The primary outcome was the change in steps per day averaged over 2-week intervals. We used mixed effects regression, adjusting for baseline step count. Secondary outcomes assessed the change in KOOS (Knee Injury and Osteoarthritis Outcome Score) over 32 weeks.</p><p><strong>Results: </strong>Thirty-one participants were included in the final analysis. Most participants were male (90.3%), Black (70.96%), had a mean (SD) age of 60 (13) years, and body mass index of 33.7 (5.9) kg/m 2 . Participants that received the intervention walked a total of 1119 (95% confidence interval: -562, 2799) more steps per day ( p = 0.19). The effect was greatest in the first 6 months (1491 [-272, 3254], p = 0.10). Compared with controls, those that received the intervention had improvement over time in total KOOS (mean 2-week change +0.62 [0.031, 1.20] vs -0.38 [-1.04, 0.28], p = 0.02) and several subscales.</p><p><strong>Conclusions: </strong>This intervention demonstrated promise for promoting greater physical activity and improving symptoms in patients with KOA.</p>","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":"336-339"},"PeriodicalIF":2.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142465900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allopurinol Adherence in US Patients With Gout: Analysis of the Medical Expenditure Panel Survey, 2018-2021.","authors":"Kevin R Riggs, Joshua S Richman, Andrea L Cherrington, Jasvinder A Singh","doi":"10.1097/RHU.0000000000002177","DOIUrl":"10.1097/RHU.0000000000002177","url":null,"abstract":"<p><strong>Background/objective: </strong>Gout is the most common inflammatory arthritis, and its morbidity can be substantially reduced through urate-lowering therapy. However, adherence to allopurinol-the most common urate-lowering therapy-is notoriously poor. Prior studies have not fully elucidated factors associated with allopurinol adherence, particularly psychosocial factors.</p><p><strong>Methods: </strong>We used 2018-2021 data from the Medical Expenditure Panel Survey, a national longitudinal survey on health care expenditures and utilization. We calculated the medication possession ratio (MPR) for allopurinol for participants with gout and categorized each as follows: no allopurinol fills, low adherence (MPR ≤0.8), or high adherence (MPR >0.8) to allopurinol. We used multivariable logistic regression to identify factors associated with high adherence, using person-year as the unit of measure and accounting for clustering for participants who contributed more than 1 person-year.</p><p><strong>Results: </strong>The analyses included 919 respondents (1453 person-years), representing a weighted total of 15,084,439 person-years. Across all years, 27.4% had no allopurinol fills, 37.4% had low adherence, and 35.2% had high adherence. In multivariable models for high adherence, Black race (odds ratio, 0.49; 95% confidence interval, 0.33-0.73, compared with White) and residence in the South US region (odds ratio, 0.54; 95% confidence interval, 0.35-0.82, compared with Northeast) were negatively associated with high adherence.</p><p><strong>Conclusions: </strong>Black race and residing in the Southern US were associated with lower allopurinol adherence among gout patients. Interventions to improve adherence, particularly among Black patients in the South, are needed to maximize the potential benefits of allopurinol.</p>","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142739507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-RA33 Antibodies Are Present in Patients With Lyme Disease.","authors":"John B Miller, Ting Yang, Alison W Rebman, Laura Cappelli, Clifton O Bingham, Marcia Daniela Villegas de Flores, Erika Darrah, John N Aucott","doi":"10.1097/RHU.0000000000002176","DOIUrl":"10.1097/RHU.0000000000002176","url":null,"abstract":"<p><strong>Background/objective: </strong>To determine if anti-RA33 antibodies, which can be seen in early forms of inflammatory arthritis, are present in patients with Lyme arthritis (LA).</p><p><strong>Methods: </strong>Anti-RA33 antibodies were tested using a commercially available assay in patients with LA (n = 47) and compared with patients with erythema migrans who returned to health (EM RTH, n = 20) and those with post-treatment Lyme disease (PTLD) (n = 50), characterized by noninflammatory arthralgia, as an observational comparative study utilizing Lyme-exposed patients from various original cohorts.</p><p><strong>Results: </strong>We found that anti-RA33 was present in higher proportions of patients with LA (23.4% vs. 0%, p = 0.001) and PTLD (12.0% vs. 0%, p = 0.040) than healthy controls. There was also a trend toward a higher percentage of anti-RA33 positivity in patients with EM RTH versus controls (10.0% vs. 0%, p = 0.080). There were no statistically significant differences among groups of patients with LA, PTLD, and EM RTH ( p ≥ 0.567). There was also no difference in the proportion of patients with antibiotic-responsive LA compared with those with persistent synovitis after antibiotics, termed post-infectious LA, and there were no differences in clinical manifestations, musculoskeletal ultrasound evaluation (synovial hypertrophy, power Doppler, tendinopathy), or patient-reported outcomes based on anti-RA33 status.</p><p><strong>Conclusions: </strong>This is the first study to identify anti-RA33 antibodies in patients with LA, though these antibodies did not identify a unique clinical subset of patients in this cohort. Unexpectedly, we found anti-RA33 antibodies at similar levels in patients with PTLD and EM RTH; further study is needed to determine the relevance of this finding.</p>","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142687050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and Imaging Pulmonary Manifestations in IgG4-Related Disease.","authors":"Jesica Romina Gallo, Cristian Froullet, Alejandro Varizat, Romina Andrea Calvo, Cecilia Pisoni, Micaela Cosatti, Ana Bertoli, Sergio Paira","doi":"10.1097/RHU.0000000000002160","DOIUrl":"https://doi.org/10.1097/RHU.0000000000002160","url":null,"abstract":"<p><strong>Objectives: </strong>The aims of this study were to describe the frequency of pleuropulmonary computed tomography (CT) findings in patients with IgG4-related disease (IgG4-RD) and to compare clinical and laboratory characteristics between patients with and without pleuropulmonary involvement in chest CT.</p><p><strong>Methods: </strong>This is a study conducted within the IgG4-RD study group of the Argentine Society of Rheumatology (GESAR IgG4) cohort of patients with IgG4-RD. Member centers of the group were requested to submit pulmonary CT scans of the patients. Lung lesions were classified into 4 subtypes: (1) nodules, (2) ground-glass opacity, (3) interstitial-alveolar involvement, and (4) bronchovascular involvement. The presence of pleural involvement and mediastinal adenopathy was also assessed.</p><p><strong>Results: </strong>We examined data from 28 patients, with 17 (61%) showing pulmonary involvement. The subtypes of pulmonary involvement, in order of frequency, were as follows: type 4 (n = 17, 100%), type 3 (n = 10, 59%), type 2 (n = 6, 36%), and type 1 (n = 5, 29%). Pleural lesions were observed in 2 (12%) cases, and mediastinal adenopathies were found in 4 (23%) cases. No demographic, clinical, or laboratory differences were noted between patients with and without pulmonary involvement, except for serum levels of IgG4, which were higher among patients without pulmonary involvement (339.0 [293.1-1592.1 mg/dL] vs 2869 [1156.3-4037.4 mg/dL]; p = 0.022).</p><p><strong>Conclusions: </strong>In this case series, the predominant subtype of pulmonary involvement was septal thickening and increased bronchovascular tissue. Patients with and without pleuropulmonary involvement exhibited similar clinical and laboratory manifestations, except for serum IgG4, which was higher in patients without pleuropulmonary involvement.</p>","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dementia and Emergency Department Use in Older Adults With Systemic Lupus Erythematosus: An Administrative Claims Data Analysis of Medicare Beneficiaries.","authors":"Sarah B Lieber, Musarrat Nahid, Iris Navarro-Millán, Mangala Rajan, Sebastian E Sattui, M Carrington Reid, Lisa A Mandl","doi":"10.1097/RHU.0000000000002066","DOIUrl":"https://doi.org/10.1097/RHU.0000000000002066","url":null,"abstract":"<p><strong>Background/objective: </strong>Systemic lupus erythematosus (SLE) is associated with increased dementia risk. Whether this association is present among older adults with SLE is unclear. Further, whether individuals with concomitant SLE and dementia are at increased risk of emergency department (ED) use has not been explored. Using US Centers for Medicare & Medicaid Services (2006-2015) administrative claims data, we (1) quantified long-term all-cause dementia prevalence in adults with SLE ≥65 years of age and (2) determined whether dementia duration is associated with risk of ED visits in a cohort of older adults with SLE relative to comparators.</p><p><strong>Methods: </strong>Medicare beneficiaries ≥65 years of age with SLE and age- and sex-matched comparators (1:4) with osteoarthritis were identified at baseline (2006). Dementia was considered a time-varying exposure, updated annually. Mixed-effect Poisson regression was used to estimate the effect of dementia duration on risk of multiple ED visits for the study period (January 2006 to September 2015), adjusting for relevant covariates.</p><p><strong>Results: </strong>Baseline dementia prevalence was similar among beneficiaries with SLE (n = 1338 [4.6%]) and non-systemic rheumatic disease (non-SRD) comparators (n = 5352 [5.7%]). Stronger association between dementia duration and ED use was observed in older adults with SLE, including after adjustment for covariates (SLE: incidence rate ratio, 1.10; 95% confidence interval, 1.07-1.13; non-SRD: incidence rate ratio, 1.05; 95% confidence interval, 1.03-1.06).</p><p><strong>Conclusions: </strong>Although dementia prevalence was similar between older adults with SLE and non-SRD comparators, dementia duration had a greater impact on ED use in aging adults with SLE versus non-SRD comparators. Geriatric assessment may be especially important in older adults with SLE.</p>","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Axial Tophaceous Gout Diagnosed by Dual-Energy CT.","authors":"Shay Brikman, Amir Bieber","doi":"10.1097/RHU.0000000000002170","DOIUrl":"https://doi.org/10.1097/RHU.0000000000002170","url":null,"abstract":"","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Calciphylaxis in Coexistent Primary and Secondary Hyperparathyroidism.","authors":"Yujia Wang, Yanfang Xu","doi":"10.1097/RHU.0000000000002173","DOIUrl":"https://doi.org/10.1097/RHU.0000000000002173","url":null,"abstract":"","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Higher Mortality Risk From Ovarian Carcinomas, Small Bowel Neoplasms, and B-Cell and Mucosa-Associated Lymphoid Tissue Lymphomas in Sjögren Syndrome Patients.","authors":"José Manuel Vázquez-Comendador, María Mateos Seirul-Lo, María Martínez-Urbistondo, Nuria Miguel-Ontañón, Antonio González-Guzmán, Román Fernández-Guitián, Raquel Castejón, Pedro Durán-Del Campo, Pablo Tutor, Susana Mellor-Pita, Víctor Moreno-Torres","doi":"10.1097/RHU.0000000000002169","DOIUrl":"https://doi.org/10.1097/RHU.0000000000002169","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the impact of the different types of neoplasms and lineages on Sjögren syndrome (SjS) patient mortality.</p><p><strong>Methods: </strong>Medical records review study based on the Spanish Hospital Discharge Database and the International Classification of Diseases, Tenth Revision, Clinical Modification coding list. The neoplasm-related deaths in SjS patients with the general population during the period 2016-2019 were compared. A binary logistic regression analysis considering age, sex, tobacco use, and alcohol use was performed to determine the impact of SjS on the risk of dying from each neoplasm group and lineage.</p><p><strong>Results: </strong>In the period studied, 705,557 in-hospital deaths were certified in Spain, 139,531 (19.8%) from neoplasms. Neoplasms surpassed SjS activity as a cause of mortality in primary SjS patients (11.3% vs. 1.6%, p < 0.001). SjS patients presented higher mortality rates from small bowel carcinoma (0.3% vs. 1.8%; odds ratio [OR], 5.41; 95% confidence interval [CI], 1.33-22) and gynecological neoplasms (6.4% vs. 3%; OR, 2.13; 95% CI, 1.01-4.58), related to ovarian carcinomas (4.6% vs. 1.3%; OR, 3.65; 95% CI, 1.48-8.97), than the general population. Hematological neoplasm-related deaths were more prevalent in SjS patients than in the non-SjS population (18.3% vs. 8.9%; OR, 2.04; 95% CI, 1.25-3.31), mostly attributable to the higher proportion of deaths from B-cell non-Hodgkin lymphoma (8.3% vs. 2.5%; OR, 3.04; 95% CI, 1.54-6.03) and mucosa-associated lymphoid tissue lymphoma (1.8% vs. 0.1%; OR, 70.17; 95% CI, 16.61-296.36).</p><p><strong>Conclusion: </strong>SjS patients face an elevated risk of mortality from small bowel neoplasms, ovarian carcinomas, and B-cell and mucosa-associated lymphoid tissue lymphoma compared with the general Spanish population. Apart from developing approaches to mitigate their occurrence, it is crucial to explore thoroughly and consider the implementation of targeted early-detection programs for these specific conditions.</p>","PeriodicalId":14745,"journal":{"name":"JCR: Journal of Clinical Rheumatology","volume":" ","pages":""},"PeriodicalIF":2.4,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143005575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}